News summary
[Zhejiang Pharmaceuticalcryptopvp: Notice of approval for clinical trials of LYSC98 for injection] Securities Times e Company NewscryptopvpZhejiang Pharmaceutical (600216) announced on the evening of May 27 that the company recently received the approval notice for the clinical trial of LYSC98 drug for injection approved and issued by the State Food and Drug Administration. LYSCcryptopvp.cryptopvp..
Newsletter text
[Zhejiang Pharmaceutical: Notice of Approval for Clinical Trials of LYSC98 for Injection] Securities Times e Company News, Zhejiang Pharmaceutical (600216) announced on the evening of May 27 that the company recently received approval and issued by the State Food and Drug Administration for Clinical Trials of LYSC98 for Injection. Notice of approval, LYSC98 (tentative name) is a new generation of new glycopeptide-resistant bacteria. It is a compound with glycolipid peptide structure that has a strong effect on clinically common gram-positive bacteria, In particular, drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus have good antibacterial activity.
